Proteinaceous therapeutics, such as antibodies and fusion proteins, for preventing, reducing the occurrence of, and/or treating a SARS-CoV-2 infection in a subject are provided herein. The methods provided herein include administering to a subject an antigen binding fragments (Fab fragment) or antibody that binds to the S ARS-CoV-2 Spike protein, ACE2 decoy peptides that bind to the SAILS-CoV-2 Spike protein, and/or a DNA construct encoding an anti-Spike Fab fragment or ACE2 decoy peptide.

The present disclosure relates to methods and kits for performing an identification of a terminal amino acid residue of the polypeptide, or performing a polypeptide sequencing. The methods include a step of contacting the terminal amino acid residue of the polypeptide with a coupler, followed by attaching the coupler-polypeptide complex to the solid support and cleaving the coupler-polypeptide complex from the polypeptide, thereby isolating the terminal amino acid residue of the polypeptide from the remaining amino acid residues of the polypeptide in complex with the coupler, thereby enabling efficient identification of the terminal amino acid residue via recognition by binding agents capable of binding to the coupler-amino acid complex. In some embodiments, the coupler and the polypeptide are both associated with stabilizing components, and after binding of the coupler to the terminal amino acid of the polypeptide, tethering complex is formed between the stabilizing components releasably attached to the solid support.

The present invention relates to the field of biochemistry, more particularly to proteomics, more particularly to protein sequencing, even more particularly to single molecule peptide sequencing. The invention discloses means and methods for single molecule protein sequencing and/or amino acid identification using cleavage inducing agent. Said cleavage inducing agents which are not specific for one particular amino acid, cleave polypeptides step by step from the N-terminus onwards and provide information on the identity of the cleaved amino acids based on the kinetics of said reaction.

Variants of chymosin with improved milk clotting properties.

The present invention provides a rapid viral nucleic acid detection kit prepared by using a novel RecA enzyme and the detection method thereof. By editing the recombinase RecA gene, the expressed RecA protein has better solubility and recombinase activity. The RecA protein is used to prepare recombinase dry powder, further the formula of the recombinase dry powder and the ratio are optimized; and specific primers for the ASFV p72 gene are designed for the rapid nucleic acid detection of ASFV, significantly improving the detection sensitivity. In addition, the detection time is short, which effectively avoids missed detection and false detection, and helps prevention of epidemic.

The present invention provides a rapid viral nucleic acid detection kit prepared by using a novel RecA enzyme and the detection method thereof. By editing the recombinase RecA gene, the expressed RecA protein has better solubility and recombinase activity. The RecA protein is used to prepare recombinase dry powder, further the formula of the recombinase dry powder and the ratio are optimized; and specific primers for the ASFV p72 gene are designed for the rapid nucleic acid detection of ASFV, significantly improving the detection sensitivity. In addition, the detection time is short, which effectively avoids missed detection and false detection, and helps prevention of epidemic.

Novel Coronavirus/MERS-CoV/Influenza Virus A/B Multiple Rapid Detection Kit is disclosed. The kit has the advantages of high sensitivity, good specificity, high speed (3-15 minutes), simplicity and low cost.

The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) including Gluten hypersensitivity. The inventors showed that ELA2A secreted by epithelial cells in the extracellular space is over-expressed in IBD conditions degrading tight junction proteins and controlling cytokines expression. Overexpression of ELA2A conferred a pro-inflammatory phenotype both in cell expression systems and in vivo in animal model of IBD. The inventors also showed that ELA2 over-expressing intestinal epithelial cells increase the release of CXCL8 protein compared to control cells. The increased CXCL-8 protein release observed in cells overexpressing ELA2A is inhibited by ELAFIN addition to the culture, in a dose-dependent manner. In particular, the invention relates to inhibitors of Elastase ELA2A, for use in the treatment of Inflammatory Bowel Diseases, such as Crohn's Disease, Ulcerative Colitis, Celiac disease, and Pouchitis.

The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) including Gluten hypersensitivity. The inventors showed that ELA2A secreted by epithelial cells in the extracellular space is over-expressed in IBD conditions degrading tight junction proteins and controlling cytokines expression. Overexpression of ELA2A conferred a pro-inflammatory phenotype both in cell expression systems and in vivo in animal model of IBD. The inventors also showed that ELA2 over-expressing intestinal epithelial cells increase the release of CXCL8 protein compared to control cells. The increased CXCL-8 protein release observed in cells overexpressing ELA2A is inhibited by ELAFIN addition to the culture, in a dose-dependent manner. In particular, the invention relates to inhibitors of Elastase ELA2A, for use in the treatment of Inflammatory Bowel Diseases, such as Crohn's Disease, Ulcerative Colitis, Celiac disease, and Pouchitis.

Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.